Artificial Intelligence

Cardiology’s AI Optimization Opportunity

Artificial intelligence and machine learning are currently having the biggest impact on imaging-related areas of cardiology, but a trio of new studies highlight AI’s potential to support significantly more cardiology treatment and therapy decisions.

Optimizing HF Treatments – University of Michigan researchers developed an algorithm that analyzes clinical data to identify HFrEF patients who would benefit from guideline-directed medical therapy (GDMT) optimization and then recommends treatment changes. 

  • When applied to data from the GUIDE-IT and HF-ACTION trials, the algorithm commonly recommended medication changes (34.9% to 68.1% of patients depending on drug) or dosage increases (48.8% of visits w/ ACR & ARBs; 39.4% of visits w/ beta-blockers).
  • The algorithm might have been right, as patients who the AI assigned better baseline GDMT scores had much lower risks of cardiovascular death or HF hospitalization (hazard ratio: 0.41) and all-cause death and hospitalization (hazard ratio: 0.61).

Predicting Post-TAVR PPM – Mayo Clinic researchers used machine learning to predict which patients would require a permanent pacemaker (PPM) after TAVR procedure more accurately than the current standard PPM prediction model.

  • Using data from 964 patients without prior PPM who underwent TAVR, the machine learning model identified 167 clinical variables to predict each patient’s PPM risk.
  • The model predicted which patients would require PPM at 30 days and one year far more accurately than the standard PPM risk score model (AUROCs: 0.66 vs. 0.55 & 0.72 vs. 0.54; both (P < 0.001).
  • Certain variables had greater association with PPMs, including brachiocephalic artery to aortic valve annulus distance to height ratio (the biggest predictor), pre-existing conduction abnormalities, trans-femoral access, and self-expanding valves.

High-Benefit BP Control – Hypertension treatment guidelines focus on high-risk patients, but targeting “high-benefit” patients for intensive BP therapy could have a much bigger population health impact. 

  • UCLA researchers used machine learning to analyze data from two BP reduction trials (n=10, 672) to identify patients who would experience the greatest benefits from intensive treatments and assess outcomes.
  • They found that providing intensive treatments to “high-benefit” patients prevented one cardiovascular event per 11 patients treated over a three-year follow-up period. 
  • That’s more than a five-times better ratio compared to exclusively targeting high-risk patients for intensive BP treatments (~62 per prevented event).

The Takeaway
This batch of studies serves as yet another reminder that AI and high-powered computing could drive a new level of personalization and precision in cardiology care, well beyond the initial diagnostic steps where we’re currently seeing most cardiology AI activities.

Get the top cardiology stories right in your inbox

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team